Currently Viewing
AACR update: Breast cancer studies offer more potential treatment options
April 10, 2014 – Debu Tripathy
The other option: Surrogacy after cancer
March 26, 2014 – Guest
So much to celebrate
March 25, 2014 – Guest
Adding surgery in metastatic kidney cancer could improve survival
March 21, 2014 – Elizabeth Whittington
Inflammation and fatigue
March 21, 2014 – Kathy LaTour
The Little Couple has cancer
March 20, 2014 – Kathy LaTour
Increased screening leads to decrease in colorectal cancer
March 18, 2014 – Elizabeth Whittington
Lynch Syndrome Awareness Day: March 22
March 18, 2014 – Elizabeth Whittington
Healing Sounds of Music Therapy
March 17, 2014 – Amy Rushlow

AACR update: Breast cancer studies offer more potential treatment options

BY Debu Tripathy
PUBLISHED April 10, 2014
Debu Tripathy blog image
Two studies announced at this year's annual meeting of the American Association for Clinical Research are targeting unique molecular features that drive breast cancer. One study is testing the drug palbociclib, which targets an abnormality in the cancer cell cycle. The drug is being tested in hormone-positive breast cancer in combination with the aromatase inhibitor, Femara (letrozone). The combination significantly delays the time it takes for the cancer to continue growing. At the current time, it's not showing a survival advantage, but a phase 3 trial in progress may be the deciding factor for the drug's approval. Another study is looking at a drug called neratinib, specifically in HER2-positive breast cancers. It's part of the I-SPY2 study, which is testing multiple new therapies before surgery, as neoadjuvant therapy. The results show that neratinib can result in complete disappearance of the tumor. This may represent a new drug for patients with HER2-positive breast cancer, including patients who have progressed on other HER2-targeted therapies. Debu Tripathy is an oncologist and editor-in-chief of CURE. He is the co-leader of the Women's Cancer Program at Norris Comprehensive Cancer Center and Professor of Medicine at the Keck School of Medicine at the University of Southern California.
Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.

Related Articles


Sign In

Not a member? Sign up now!

Sign Up

Are you a member? Please Log In